Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome.
BACKGROUND
Chronic mild endogenous glucocorticoid excess has been shown to cause bone loss and to increase fracture risk in both post-menopausal and premenopausal women. Currently, it is unclear if patients with subclinical Cushing's syndrome (SCS) with osteoporosis or osteopenia may benefit from antiresorptive treatment and the type of therapy to be given.


OBJECTIVE
This pilot randomized study was aimed at evaluating the effects of 12-month im administration of clodronate (100 mg every week) on vertebral and femoral bone mineral density (BMD), bone turnover markers and on subjective pain in premenopausal women with SCS due to adrenal incidentalomas.


METHODS
Forty-six women (age, 43.1+/-7.7 yr) with SCS due to adrenal incidentaloma and osteoporosis/osteopenia were randomized to receive clodronate plus supplement of Calcium (500 mg daily) and Vitamin D3 (800 mg daily) (group 1, no.=23) or supplements only (group 2, no.=23). Both groups were similar in terms of age, body mass index, cortisol levels, BMD values, and bone turnover markers. All of the women were re-evaluated after 12 months.


RESULTS
After 12 months of treatment, in group 1, a significant increase in lumbar BMD occurred (p=0.04), while bone turnover markers decreased by about one third (p<0.05). In group 2, bone turnover markers did not change and BMD values slightly decreased (p=ns). The differences in bone turnover markers and in lumbar BMD between the two groups were significant (p<0.05, all). No new vertebral fracture occurred in group 1, while in group 2 the spine radiographies revealed 2 new fractures and a worsening of two pre-existent fractures. An improvement in subjective back pain, assessed by visual analogue scale pain score was observed in group 1 (from 4.3+/-2.7 to 2.9+/-2.0; p<0.05) but not in group 2 (from 4.4+/-3.1 to 4.2+/-3.4; p=ns). No significant changes occurred in cortisol secretion or clinical picture of the SCS during the study.


CONCLUSIONS
Intramuscular administration of clodronate effectively increased lumbar BMD values, preserved bone mass at the femoral neck, stabilized vertebral fracture index, and decreased subjective back pain in pre-menopausal women with SCS. Since the untreated group continued to lose bone, antiresorptive treatment should be considered in patients with SCS, according to the prevision of surgical treatment, prevalent fractures, BMD values, age, concomitant morbidities, and desire for pregnancy.
Tauchmanova
L
L
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy. tauchman@unina.it
Guerra
E
E
Pivonello
R
R
De Martino
M C
MC
De Leo
M
M
Caggiano
F
F
Lombardi
G
G
Colao
A
A
D000236:Adenoma / Q000150:complications / Q000188:drug therapy; D000284:Administration, Oral; D000310:Adrenal Gland Neoplasms / Q000150:complications / Q000188:drug therapy; D000328:Adult; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects; D001862:Bone Resorption / Q000209:etiology / Q000517:prevention & control*; D002118:Calcium / Q000008:administration & dosage; D002762:Cholecalciferol / Q000008:administration & dosage; D004002:Clodronic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D003480:Cushing Syndrome / Q000150:complications / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control*
D050071:Bone Density Conservation Agents; D004002:Clodronic Acid; D002762:Cholecalciferol; D002118:Calcium